Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 589

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Micrometastases and Survival in Stage II Colorectal Cancer

Open access
Liefers, Gerrit-Jan, Cleton-Jansen, Anne-Marie, van de Velde, Cornelis J.H., Hermans, Jo, van Krieken, Johannes H.J.M., Cornelisse, Cees J., Tollenaar, Rob A.E.M.·1998·New England Journal of Medicine

Abstract

BACKGROUND: Standard treatment of colorectal cancer includes adjuvant chemotherapy for patients with stage III disease (defined by the presence of lymph-node metastases), but not for patients with stage II tumors (who have no lymph-node metastases). However, 20 percent of patients with stage II tumors die of recurrent disease. We investigated whether the detection of micrometastases can be used to identify patients with stage II disease who are at high risk for recurrence. METHODS: We analyzed 192 lymph nodes from 26 consecutive patients with stage II colorectal cancer, using a carcinoembryonic antigen-specific nested reverse-transcriptase polymerase chain reaction. Five-year follow-up information was obtained on all patients. Observed and adjusted survival rates were assessed in the patients with and the patients without micrometastases. RESULTS: Micrometastases were detected in one or more lymph nodes from 14 of 26 patients (54 percent). The adjusted five-year survival rate (for which only cancer-related deaths were considered) was 50 percent in this group, whereas in the 12 patients without micrometastases, the survival rate was 91 percent (P=0.02 by the log-rank test). The observed five-year survival rates were 36 percent and 75 percent, respectively (P=0.03). The groups were similar with respect to age, sex, tumor side (location in relation to the flexura lienalis), degree of tumor differentiation (grade), and diameter of the primary tumor. CONCLUSIONS: Molecular detection of micrometastases is a prognostic tool in stage II colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199807233390403

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 589

Metadata

Authors
Liefers, G.-J., Cleton-Jansen, A.-M., van de Velde, C. J. H., Hermans, J., van Krieken, J. H. J. M., Cornelisse, C. J., & Tollenaar, R. A. E. M.
Venue
New England Journal of Medicine
Published
1998-07-23
Volume
339
Issue
4
Pages
223-228
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2339671919
Cited by
589
References
20
FWCI
21.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Micrometastases and Survival in Stage II Colorectal Cancer. https://app.cochat.ai/papers/10.1056/nejm199807233390403
The paper
Liefers, G.-J., Cleton-Jansen, A.-M., van de Velde, C. J. H., Hermans, J., van Krieken, J. H. J. M., Cornelisse, C. J., & Tollenaar, R. A. E. M. (1998). Micrometastases and Survival in Stage II Colorectal Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejm199807233390403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.